ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0784

Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America

Laura Cannon1, Scott Wenderfer2, Laura Lewandowski3, Jennifer Cooper4, Beatrice Goilav5, Andrea Knight6, Aimee Hersh7, Stacy Ardoin8 and Rebecca Sadun1, 1Duke University, Durham, NC, 2Baylor College of Medicine, Houston, TX, 3NIAMS, NIH, Rockville, MD, 4University of Colorado/Children's Hospital Colorado, Denver, CO, 5Children's Hospital at Montefiore, Bronx, NY, 6Hospital for Sick Children, Toronto, ON, Canada, 7University of Utah, Salt Lake City, UT, 8Nationwide Children's Hospital, Columbus, OH

Meeting: ACR Convergence 2021

Keywords: Lupus nephritis, Pediatric rheumatology, Surveys, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Title: Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) has higher rates of lupus nephritis (LN) than adult-onset SLE, often requiring intensive immunosuppression. This study examined North American practices and preferences for the low-dose EuroLupus cyclophosphamide protocol, as compared to the high-dose National Institute of Health (NIH) cyclophosphamide protocol, to treat LN in cSLE.

Methods: A 35-item web-based survey was distributed to Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Pediatric Nephrology Research Consortium (PNRC) providers. The survey assessed participant demographics, cyclophosphamide prescribing practices, perceptions of EuroLupus protocol, and LN vignette treatment decisions; one vignette was taken from a 2009 CARRA survey and responses were compared. Multivariable logistic regression analyzed provider factors associated with practices and preference for low- versus high-dose cyclophosphamide.

Results: Responses were provided by 185/421 (44%) CARRA physicians (Table 1). Among respondents who prescribed cyclophosphamide for pediatric LN over the past year (n=135), half reported using EuroLupus protocol. When presented the same vignette about an adolescent with class IV LN, 32% of pediatric rheumatologists chose EuroLupus dosing in 2020, versus only 6% in 2009 (Figure 1). Provider factors associated with choosing the low-dose regimen were familiarity with the protocol (OR 4.2, p=0.006) and greater perceived benefit (OR 1.6, p< 0.0001) (Table 2). Forty pediatric nephrologists had similar responses to the pediatric rheumatology providers. Overall, 78% of respondents perceived EuroLupus protocol efficacy to be equivalent to the high-dose protocol in cSLE LN.

Conclusion: Of pediatric specialists who prescribe cyclophosphamide for cSLE LN, more use low-dose cyclophosphamide compared to a decade prior. Nevertheless, familiarity with EuroLupus dosing remains low.

Table 1. Demographics of survey respondents.
CARRA=Childhood Arthritis and Rheumatology Research Alliance
PNRC=Pediatric Nephrology Research Consortium
IV=intravenous
LN=lupus nephritis

Figure 1. Change over a decade in pediatric rheumatologist preferences for first-line treatment of lupus nephritis in childhood-onset systemic lupus erythematosus. Survey respondents from the Childhood Arthritis and Rheumatology Research Alliance membership (n=134) were presented with the same clinical vignette that had been posed in 2009 (n=71) regarding first-line therapy for newly diagnosed SLE with class IV lupus nephritis in a 14-year-old girl.
CYC=cyclophosphamide
MMF=mycophenolate mofetil
EL= EuroLupus
NIH= National Institute of Health

Table 2. Provider factors associated with use of EuroLupus cyclophosphamide dosing based on results of logistic regression models.
Shown are the results from a logistic regression model comparing provider factors for those selecting EuroLupus dosing vs NIH dosing who had prescribed cyclophosphamide for pediatric LN over the past 12 months (n=135).
NIH= National Institute of Health
LN= lupus nephritis


Disclosures: L. Cannon, None; S. Wenderfer, Bristol-Myers Squibb, 2; L. Lewandowski, None; J. Cooper, None; B. Goilav, None; A. Knight, None; A. Hersh, None; S. Ardoin, Aurinia, 2, American Board of Pediatrics, 4, Childhood Arthritis and Rheumatology Research Alliance, 4; R. Sadun, None.

To cite this abstract in AMA style:

Cannon L, Wenderfer S, Lewandowski L, Cooper J, Goilav B, Knight A, Hersh A, Ardoin S, Sadun R. Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/use-of-eurolupus-cyclophosphamide-dosing-for-the-treatment-of-lupus-nephritis-in-childhood-onset-systemic-lupus-erythematosus-in-north-america/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-eurolupus-cyclophosphamide-dosing-for-the-treatment-of-lupus-nephritis-in-childhood-onset-systemic-lupus-erythematosus-in-north-america/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology